Cancer-Related Fatigue in Patients With Metastatic… : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
Jorge J. Nieva, MD, details the benefits of telemedicine and a first-of-its-kind clinical trial where patients with NSCLC will receive subcutaneous immunotherapy at home.
The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing to personalize treatment…
Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.
The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
An abstract is unavailable.
Tumor-infiltrating B lymphocytes were associated with worse outcomes in patients with metastatic ccRCC treated with axitinib plus anti–PD-1 therapy.
An abstract is unavailable.
An abstract is unavailable.
Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.